Big pharma company wants to invest in eye care, bought the biggest kid on the block of eye care. Big pharma takes all ideas, projects and pipeline, fires all scientists.. Big pharma company drain the big kid and takes all assets, THEN sells the big kid (now a big loser) to become the biggest kid again, it will take years, chances are that will never happen. The kid will have to go out of business... Novartis will sell Alcon, Alcon will go out of business, and might merge with ...??????
That's non-sense. They bought the "big kid", thinking the big kid would continue providing double digit growth, as it had been doing for the previous decade. Problem is Kevin has had his head up his ass during his tenure at Alcon, and never learned the market that Alcon owned, he had no understanding of the formula that enabled that growth, nor did Sabri (two big dummies). NVS came in with their big pharma mentality and implemented it and it crippled the "big kid", no thanks to Kevin, who should have been a champion for Alcon and it's success, and told Novartis, hands off, leave us alone, we'll continue to deliver. But instead his short sighted balance sheet driven management, is a direct result of screwing the sales force by posting ridiculous sales targets, and the R&D pipeline is as a clean as a freshly changed diaper, alternatively the culture of R&D resembles a full diaper. Alcon is only going to come out of this if there is a change at the top, but that ain't happening anytime soon.
After almost three years in the allegedly superior Alcon environment, LASR and GPS have been exposed as really meaning Lazy Alcon Sales Reps Giving Product Samples. Selling? Alcon reps don't know the first thing about it nor do douchebags like Brandon Bazzell, Brian MacGrew, or Kris Petersen. Three Stooges is an accurate description.
The only incompetent folks I've encountered at Alcon were at Alcon before Novartis bought them. Brandon Bazzell ring a bell? LOL
What Novartis did not know when they bought this company was that Alcon became the big kid by buying and manipulating their customers for years. Bribes, kickbacks, payoffs, and not investing in any kind of infrastructure whatsoever is what led to double digit growth all those years. Eyecare was the wild west and Alcon was the biggest kid in town (Jabba the Hutt?). Unfortunately for Novartis they cannot tolerate that type of behavior as the liability is too huge (apparently only in the US, as Asian areas it seems to be encouraged). So here we are. Welcome to the crossroads.
